Diproteverine HCl is a novel calcium antagonist with antianginal properties, antispasmodic and vasoactive.

Diproteverine (1 μM; sheep Purkinje fibers) to reduce the amplitude of the slow action potential (IC30 = 2 μM) and to shorten the duration of the fast action potential at 50% repolarisation (IC30 = 2.5 μM). Papaverine was found to possess marginal membrane channel-blocking activity and to be much more potent than diproteverine as a cAMP-phosphodiesterase inhibitor (IC50 = 8 μM).[2]

Diproteverine (0.25-0.75 mg/kg; i.e.; dog; at plasma levels within the assumed therapeutic range) dose-relatedly decreases heart rate, increases corrected sinus node recovery time, and decreases Wenckebach point. These effects are observed at plasma levels ranging between 16.2 +/- 4.1 and 144.7 +/- 12.5 ng/ml. After cholinergic blockade with N-methylscopolammonium, diproteverine lowers heart rate (greater than or equal to 0.25 mg/kg), increases corrected sinus node recovery time, and decreases Wenckebach point (greater than or equal to 0.5 mg/kg). After propranolol, diproteverine only significantly reduces corrected sinus node recovery time 5 min after the third administration (0.75 mg/kg). After pharmacologic autonomic blockade by N-methylscopolammonium propranolol combination, diproteverine lowers the intrinsic heart rate (greater than or equal to 0.25 mg/kg) and Wenckebach point (greater than or equal to 0.5 mg/kg). Diproteverine does not modify mean blood pressure. These results show that diproteverine administered with and without pharmacologic autonomic blockade in the conscious dog causes dose-related depressant effects on sinus node function and atrioventricular conduction without producing significant vasodilatation.[1]

DMSO: 55 mg/mL (119.04 mM), Sonication is recommended.